Symbols / KYTX $8.87 -2.42%
KYTX Chart
About
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 528.71M |
| Enterprise Value | 231.99M | Income | -160.99M | Sales | — |
| Book/sh | 3.47 | Cash/sh | 3.91 | Dividend Yield | — |
| Payout | 0.00% | Employees | 129 | IPO | — |
| P/E | — | Forward P/E | -2.62 | PEG | — |
| P/S | — | P/B | 2.56 | P/C | — |
| EV/EBITDA | -1.36 | EV/Sales | — | Quick Ratio | 5.05 |
| Current Ratio | 5.16 | Debt/Eq | 3.31 | LT Debt/Eq | — |
| EPS (ttm) | -3.73 | EPS next Y | -3.39 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 | ROA | -40.75% |
| ROE | -70.82% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 59.61M |
| Shs Float | 24.37M | Short Float | 10.17% | Short Ratio | 6.38 |
| Short Interest | — | 52W High | 13.67 | 52W Low | 1.78 |
| Beta | 3.35 | Avg Volume | 928.82K | Volume | 482.87K |
| Target Price | $29.60 | Recom | Strong_buy | Prev Close | $9.09 |
| Price | $8.87 | Change | -2.42% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$29.60
Mean price target
2. Current target
$8.87
Latest analyst target
3. DCF / Fair value
$-28.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.87
Low
$20.00
High
$33.00
Mean
$29.60
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-16 | main | Wells Fargo | Overweight → Overweight | $33 |
| 2025-12-04 | main | Morgan Stanley | Overweight → Overweight | $25 |
| 2025-10-30 | main | Wells Fargo | Overweight → Overweight | $31 |
| 2025-10-27 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-10-08 | main | Wells Fargo | Overweight → Overweight | $27 |
| 2025-08-29 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-08-20 | init | William Blair | — → Outperform | — |
| 2025-05-27 | up | HC Wainwright & Co. | Neutral → Buy | $5 |
| 2025-04-03 | main | HC Wainwright & Co. | Neutral → Neutral | $4 |
| 2025-04-01 | main | Morgan Stanley | Overweight → Overweight | $20 |
| 2024-11-20 | main | HC Wainwright & Co. | Neutral → Neutral | $6 |
| 2024-11-15 | main | Wells Fargo | Overweight → Overweight | $24 |
| 2024-10-10 | init | UBS | — → Buy | $13 |
| 2024-09-19 | reit | HC Wainwright & Co. | Neutral → Neutral | $7 |
| 2024-08-15 | main | HC Wainwright & Co. | Neutral → Neutral | $7 |
| 2024-07-31 | main | JP Morgan | Overweight → Overweight | $33 |
| 2024-07-16 | reit | HC Wainwright & Co. | Neutral → Neutral | $8 |
| 2024-07-03 | init | HC Wainwright & Co. | — → Neutral | $8 |
| 2024-03-04 | init | JP Morgan | — → Overweight | $39 |
| 2024-03-04 | init | Morgan Stanley | — → Overweight | $40 |
- Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat ue, 17 Mar 2026 08
- $KYTX stock is up 11% today. Here's what we see in our data. - Quiver Quantitative ue, 10 Mar 2026 19
- Biotech Kyverna prices $100M stock sale amid autoimmune cell therapy focus - Stock Titan Wed, 17 Dec 2025 08
- KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data - Yahoo Finance ue, 16 Dec 2025 08
- Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution - Seeking Alpha ue, 03 Mar 2026 06
- KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome? - Stocktwits Mon, 15 Dec 2025 08
- Kyverna Therapeutics (NASDAQ: KYTX) launches $100M stock sale with $15M underwriters’ option - Stock Titan Mon, 15 Dec 2025 08
- Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout - Yahoo Finance Fri, 17 Oct 2025 07
- Director at Kyverna Therapeutics (KYTX) granted options and RSUs - Stock Titan hu, 26 Feb 2026 08
- Kyverna adds Karuna founder from $14B Bristol Myers buyout to its board - Stock Titan ue, 24 Feb 2026 08
- Kyverna (Nasdaq: KYTX) SPS CAR-T meets Phase 2 goals, plans 1H 2026 BLA filing - Stock Titan Mon, 15 Dec 2025 08
- Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock - Quiver Quantitative Wed, 17 Dec 2025 08
- Kyverna Therapeutics (NASDAQ: KYTX) schedules Dec. 15 KYSA-8 topline SPS data call - Stock Titan Sun, 14 Dec 2025 08
- Insider Sale: Chief Technology Officer of $KYTX Sells 23,998 Shares - Quiver Quantitative hu, 18 Dec 2025 08
- New cell therapy data in stiff person syndrome set for AAN 2026 - Stock Titan hu, 05 Mar 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 11006 | — | — | Stock Award(Grant) at price 0.00 per share. | MILLER ANDREW CRAIG | Director | — | 2026-02-24 00:00:00 | D |
| 1 | 11006 | — | — | Stock Award(Grant) at price 0.00 per share. | EMANY SRAVAN KUMAR | Director | — | 2026-02-24 00:00:00 | D |
| 2 | 54301 | — | — | Stock Award(Grant) at price 0.00 per share. | SHAW CHRISTI L | Officer and Director | — | 2026-01-12 00:00:00 | D |
| 3 | 133333 | 999998 | — | Purchase at price 7.50 per share. | SEIDENBERG BETH C | Director | — | 2025-12-18 00:00:00 | I |
| 4 | 133333 | 999998 | — | Purchase at price 7.50 per share. | WESTLAKE BIOPARTNERS FUND I, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-18 00:00:00 | I |
| 5 | 23998 | 115910 | — | Conversion of Exercise of derivative security at price 4.83 per share. | WALKER KAREN MARIE | Chief Technology Officer | — | 2025-12-15 00:00:00 | D |
| 6 | 23998 | 292776 | — | Sale at price 12.20 per share. | WALKER KAREN MARIE | Chief Technology Officer | — | 2025-12-15 00:00:00 | D |
| 7 | 16634 | — | — | Stock Award(Grant) at price 0.00 per share. | SPIEGELMAN DANIEL KEITH | Director | — | 2025-05-29 00:00:00 | D |
| 8 | 16634 | — | — | Stock Award(Grant) at price 0.00 per share. | CLARK IAN THORNTON | Director | — | 2025-05-29 00:00:00 | D |
| 9 | 16634 | — | — | Stock Award(Grant) at price 0.00 per share. | COHEN FREDERICK E. M.D. PH.D. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-05-29 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -125.20M | -58.47M | -27.78M | -25.76M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -127.48M | -60.37M | -28.89M | -26.35M |
| ReconciledDepreciation | 2.13M | 1.71M | 1.05M | 586.00K |
| EBITDA | -125.20M | -58.47M | -27.78M | -25.76M |
| EBIT | -127.33M | -60.18M | -28.83M | -26.35M |
| NetInterestIncome | 15.22M | 2.10M | 500.00K | -2.00K |
| InterestExpense | 142.00K | 187.00K | 65.00K | 3.00K |
| InterestIncome | 15.36M | 2.28M | 565.00K | 1.00K |
| NormalizedIncome | -127.48M | -60.37M | -28.89M | -26.35M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -127.48M | -60.37M | -28.89M | -26.35M |
| TotalExpenses | 142.60M | 62.41M | 36.41M | 32.00M |
| TotalOperatingIncomeAsReported | -142.60M | -62.41M | -29.38M | -26.35M |
| DilutedAverageShares | 38.33M | 40.82M | 25.80M | 25.80M |
| BasicAverageShares | 38.33M | 40.82M | 25.80M | 25.80M |
| DilutedEPS | -3.33 | -1.48 | -1.12 | -1.02 |
| BasicEPS | -3.33 | -1.48 | -1.12 | -1.02 |
| DilutedNIAvailtoComStockholders | -127.48M | -60.37M | -28.89M | -26.35M |
| NetIncomeCommonStockholders | -127.48M | -60.37M | -28.89M | -26.35M |
| NetIncome | -127.48M | -60.37M | -28.89M | -26.35M |
| NetIncomeIncludingNoncontrollingInterests | -127.48M | -60.37M | -28.89M | -26.35M |
| NetIncomeContinuousOperations | -127.48M | -60.37M | -28.89M | -26.35M |
| PretaxIncome | -127.48M | -60.37M | -28.89M | -26.35M |
| OtherIncomeExpense | -90.00K | -55.00K | -9.00K | -2.00K |
| OtherNonOperatingIncomeExpenses | -90.00K | -55.00K | -9.00K | -2.00K |
| NetNonOperatingInterestIncomeExpense | 15.22M | 2.10M | 500.00K | -2.00K |
| InterestExpenseNonOperating | 142.00K | 187.00K | 65.00K | 3.00K |
| InterestIncomeNonOperating | 15.36M | 2.28M | 565.00K | 1.00K |
| OperatingIncome | -142.60M | -62.41M | -29.38M | -26.35M |
| OperatingExpense | 142.60M | 62.41M | 36.41M | 32.00M |
| ResearchAndDevelopment | 112.47M | 49.92M | 28.40M | 25.85M |
| SellingGeneralAndAdministration | 30.13M | 12.48M | 8.01M | 6.15M |
| GeneralAndAdministrativeExpense | 30.13M | 12.48M | 8.01M | 6.15M |
| OtherGandA | 30.13M | 12.48M | 8.01M | 6.15M |
| TotalRevenue | 0.00 | 0.00 | 7.03M | 5.66M |
| OperatingRevenue | 0.00 | 0.00 | 7.03M | 5.66M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 43.21M | 43.12M | 40.82M | 40.82M |
| ShareIssued | 43.21M | 43.12M | 40.82M | 40.82M |
| TotalDebt | 8.24M | 9.08M | 10.56M | 5.55M |
| TangibleBookValue | 266.59M | -131.40M | -74.00M | -46.25M |
| InvestedCapital | 266.59M | -131.40M | -74.00M | -46.25M |
| WorkingCapital | 256.85M | 40.80M | 41.30M | 61.16M |
| NetTangibleAssets | 266.59M | -131.40M | -74.00M | -46.25M |
| CapitalLeaseObligations | 8.24M | 9.08M | 10.56M | 5.55M |
| CommonStockEquity | 266.59M | -131.40M | -74.00M | -46.25M |
| TotalCapitalization | 266.59M | -131.40M | -74.00M | -46.25M |
| TotalEquityGrossMinorityInterest | 266.59M | -131.40M | -74.00M | -46.25M |
| StockholdersEquity | 266.59M | -131.40M | -74.00M | -46.25M |
| GainsLossesNotAffectingRetainedEarnings | 105.00K | 4.00K | -26.00K | 0.00 |
| OtherEquityAdjustments | 105.00K | 4.00K | -26.00K | |
| RetainedEarnings | -263.52M | -136.04M | -75.68M | -46.78M |
| AdditionalPaidInCapital | 530.00M | 4.64M | 1.71M | 530.00K |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 38.06M | 206.59M | 140.92M | 131.74M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 4.30M | 186.73M | 128.97M | 115.81M |
| OtherNonCurrentLiabilities | 6.00K | 78.00K | ||
| PreferredSecuritiesOutsideStockEquity | 0.00 | 180.57M | 120.67M | 108.72M |
| NonCurrentAccruedExpenses | 0.00 | 1.25M | ||
| NonCurrentDeferredLiabilities | 0.00 | 1.02M | ||
| NonCurrentDeferredRevenue | 0.00 | 1.02M | ||
| LongTermDebtAndCapitalLeaseObligation | 4.30M | 6.16M | 8.29M | 4.74M |
| LongTermCapitalLeaseObligation | 4.30M | 6.16M | 8.29M | 4.74M |
| CurrentLiabilities | 33.76M | 19.86M | 11.95M | 15.93M |
| OtherCurrentLiabilities | 3.52M | 565.00K | 575.00K | |
| CurrentDeferredLiabilities | 0.00 | 6.00M | ||
| CurrentDeferredRevenue | 0.00 | 6.00M | ||
| CurrentDebtAndCapitalLeaseObligation | 3.94M | 2.92M | 2.28M | 814.00K |
| CurrentCapitalLeaseObligation | 3.94M | 2.92M | 2.28M | 814.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.88M | 2.81M | 1.41M | 1.14M |
| PayablesAndAccruedExpenses | 24.93M | 14.13M | 7.70M | 7.40M |
| CurrentAccruedExpenses | 20.31M | 9.77M | 6.25M | 6.62M |
| Payables | 4.62M | 4.36M | 1.45M | 773.00K |
| AccountsPayable | 4.62M | 4.36M | 1.45M | 773.00K |
| TotalAssets | 304.64M | 75.19M | 66.92M | 85.49M |
| TotalNonCurrentAssets | 14.04M | 14.53M | 13.67M | 8.40M |
| OtherNonCurrentAssets | 3.39M | 3.92M | 1.23M | 593.00K |
| NetPPE | 10.66M | 10.61M | 12.44M | 7.81M |
| AccumulatedDepreciation | -3.67M | -2.49M | -1.62M | -842.00K |
| GrossPPE | 14.33M | 13.10M | 14.06M | 8.65M |
| Leases | 821.00K | 645.00K | 456.00K | 75.00K |
| OtherProperties | 11.44M | 11.69M | 12.93M | 8.15M |
| MachineryFurnitureEquipment | 2.07M | 760.00K | 672.00K | 422.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 290.60M | 60.66M | 53.25M | 77.09M |
| OtherCurrentAssets | 4.62M | 3.12M | 1.93M | 1.02M |
| CashCashEquivalentsAndShortTermInvestments | 285.98M | 57.54M | 51.32M | 76.07M |
| OtherShortTermInvestments | 189.36M | 22.90M | 13.59M | 0.00 |
| CashAndCashEquivalents | 96.62M | 34.65M | 37.73M | 76.07M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -116.45M | -53.03M | -36.88M | -23.44M |
| RepaymentOfDebt | -956.00K | -781.00K | -249.00K | -41.00K |
| IssuanceOfCapitalStock | 341.17M | 59.90M | 11.95M | 72.53M |
| CapitalExpenditure | -2.21M | -621.00K | -768.00K | -1.29M |
| InterestPaidSupplementalData | 142.00K | 187.00K | 65.00K | 3.00K |
| EndCashPosition | 97.17M | 35.21M | 38.29M | 76.62M |
| BeginningCashPosition | 35.21M | 38.29M | 76.62M | 27.54M |
| ChangesInCash | 61.96M | -3.08M | -38.33M | 49.08M |
| FinancingCashFlow | 337.11M | 58.12M | 11.88M | 72.52M |
| CashFlowFromContinuingFinancingActivities | 337.11M | 58.12M | 11.88M | 72.52M |
| NetOtherFinancingCharges | -3.36M | -1.65M | ||
| ProceedsFromStockOptionExercised | 259.00K | 645.00K | 175.00K | 30.00K |
| NetPreferredStockIssuance | 0.00 | 59.90M | 11.95M | 72.53M |
| PreferredStockIssuance | 0.00 | 59.90M | 11.95M | 72.53M |
| NetCommonStockIssuance | 341.17M | 0.00 | ||
| CommonStockIssuance | 341.17M | 0.00 | ||
| NetIssuancePaymentsOfDebt | -956.00K | -781.00K | -249.00K | -41.00K |
| NetLongTermDebtIssuance | -956.00K | -781.00K | -249.00K | -41.00K |
| LongTermDebtPayments | -956.00K | -781.00K | -249.00K | -41.00K |
| InvestingCashFlow | -160.90M | -8.79M | -14.10M | -1.29M |
| CashFlowFromContinuingInvestingActivities | -160.90M | -8.79M | -14.10M | -1.29M |
| NetInvestmentPurchaseAndSale | -158.70M | -8.16M | -13.33M | 0.00 |
| SaleOfInvestment | 331.30M | 46.68M | 43.17M | 0.00 |
| PurchaseOfInvestment | -490.00M | -54.85M | -56.49M | 0.00 |
| NetPPEPurchaseAndSale | -2.21M | -621.00K | -768.00K | -1.29M |
| PurchaseOfPPE | -2.21M | -621.00K | -768.00K | -1.29M |
| OperatingCashFlow | -114.25M | -52.41M | -36.11M | -22.16M |
| CashFlowFromContinuingOperatingActivities | -114.25M | -52.41M | -36.11M | -22.16M |
| ChangeInWorkingCapital | 7.86M | 3.42M | -10.33M | -4.49M |
| ChangeInOtherWorkingCapital | -7.03M | -5.66M | ||
| ChangeInOtherCurrentLiabilities | -2.40M | -1.68M | -1.08M | -228.00K |
| ChangeInOtherCurrentAssets | -1.96M | -1.85M | -637.00K | -39.00K |
| ChangeInPayablesAndAccruedExpense | 13.71M | 8.14M | -678.00K | 2.15M |
| ChangeInAccruedExpense | 12.98M | 4.06M | -1.35M | 2.14M |
| ChangeInPayable | 736.00K | 4.08M | 677.00K | 11.00K |
| ChangeInAccountPayable | 736.00K | 4.08M | 677.00K | 11.00K |
| ChangeInPrepaidAssets | -1.50M | -1.19M | -909.00K | -722.00K |
| OtherNonCashItems | 2.54M | 1.72M | 1.41M | 829.00K |
| StockBasedCompensation | 8.36M | 2.22M | 929.00K | 7.25M |
| AmortizationOfSecurities | -7.66M | -1.11M | -284.00K | 0.00 |
| DepreciationAmortizationDepletion | 2.13M | 1.71M | 1.05M | 586.00K |
| DepreciationAndAmortization | 2.13M | 1.71M | 1.05M | 586.00K |
| OperatingGainsLosses | 21.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 21.00K | ||
| NetIncomeFromContinuingOperations | -127.48M | -60.37M | -28.89M | -26.35M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for KYTX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|